- authorisedTherapeutic exploratory (Phase II)
OSU6162 in Bipolar Depression: An Open-label, Flexible Dose Study (OBID)
This study is looking into a new medication called OSU6162 for people with bipolar depression. It hopes to see if this medicine can help improve symptoms of depression. Participants will take the medicine, and doctors will monitor their mood over a couple of months.
Sweden - recruitingPHASE3
The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
This study looks at how new treatments for bipolar depression, like different medications, compare to usual care. It's for people whose first treatment for bipolar depression didn't quite work. The aim is to find better ways to help people whose mood swings include significant depression.
Austria · Germany · Greece - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A study to evaluate the effect of multiple doses of carbamazepine and itraconazole on how long JNJ-55308942 stays in the body (pharmacokinetics) in healthy adults.
This study is looking at how a new medicine, JNJ-55308942, moves through the body of healthy adults when taken with other common medicines. It's an early-stage study to understand how different medicines might affect each other, which is important for treating conditions like bipolar depression.
Belgium - recruitingNA
SYNCED - SYNChronized Eating in Bipolar Depression Study
This study looks at a new way to help people with bipolar depression by changing when they eat. It's called 'time-restricted eating' and might help improve mood and overall well-being alongside usual care.
Canada